{"id":61441,"date":"2021-11-09T04:58:14","date_gmt":"2021-11-09T04:58:14","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=82158"},"modified":"2021-11-09T04:58:14","modified_gmt":"2021-11-09T04:58:14","slug":"nyxoah-appoints-new-cfo","status":"publish","type":"post","link":"https:\/\/lebanonnewsgazette.com\/nyxoah-appoints-new-cfo\/","title":{"rendered":"Nyxoah appoints new CFO"},"content":{"rendered":"
\n

Mont-Saint-Guibert, Belgium \u2013 November 8, 2021, 10:30pm CET \/ 4:30pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/b>(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Lo\u00efc Moreau will join Nyxoah as CFO as of January 1, 2022.<\/p>\n

Lo\u00efc will join Nyxoah from GSK, where he held leadership roles in Finance across various geographies. Prior to GSK, Lo\u00efc built his career at EY and PwC. Lo\u00efc holds an executive master in Finance. He will replace current CFO, Fabian Suarez, who will leave Nyxoah at the end of 2021 to pursue a new opportunity as CEO of a startup MedTech company.<\/p>\n

Olivier Taelman, CEO, commented: \u201cWe are very grateful to Fabian for his hard work, dedication and leadership over the last seven years. During his time at Nyxoah, Fabian led the Finance department and served as a valued and trusted member of the management team. He was instrumental in securing the successful Euronext Brussels and Nasdaq IPOs during the last year, and we wish him all the best in his new endeavor. We look forward to a smooth transition.\u201d<\/p>\n

Fabian Suarez added: \u201cAfter seven years at Nyxoah, which I profoundly enjoyed, it is time for the next step in my career development.\u00a0\u00a0I am proud to have been part of Nyxoah and its exciting journey, and I look forward to Nyxoah\u2019s many future successes.\u201d<\/p>\n

About Nyxoah<\/b>
\nNyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah\u2019s lead solution is the Genio\u00ae system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world\u2019s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.<\/p>\n

Following the successful completion of the BLAST OSA study, the Genio\u00ae system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE-Mark indication approval to treat Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors\u2019 therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.<\/p>\n

For more information, please visit\u00a0http:\/\/www.nyxoah.com\/<\/u><\/a>.<\/p>\n

Caution\u00a0<\/b>\u2013 CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.<\/p>\n

Contacts:<\/b><\/p>\n

Nyxoah<\/b>
\nJeremy Feffer, VP IR and Corporate Communications
\njeremy.feffer@nyxoah.com<\/a>
\n+1 917 749 1494<\/p>\n

Gilmartin Group\u00a0<\/b>
\nVivian Cervantes
\nIR@nyxoah.com<\/a><\/p>\n

Attachment<\/strong><\/p>\n